China Doll

Birthday and cancerversaries became bittersweet as I was dealing with the realities of cancer, the side effects, the constant fear of the unknown, the helplessness, the indignity of losing who you are, who you were, even things you take for granted like walking up your own stairs or getting out the bath (because the treatment has made you weak).

And so, I feel with every year I am living with MBC, with every new treatment and with every progression, I am like a china doll. Leaving broken pieces of me behind.  

The Irony of Metastatic Breast Cancer – Mary Huckle

Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a

On the trail of a Clinical Trial…

On the trail of a Clinical Trial…

METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.

Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?

And where do patients start when looking for a metastatic trial themselves?

Trodelvy Now! Latest Update

Trodelvy Approved by NICE

METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.